Abstract: The present invention relates to bispecific antibodies having activity against a vascular endothelial growth factor (VEGF) and an angiopoietin (ANG), and methods of making and using such bispecific antibodies.
Type:
Grant
Filed:
August 22, 2017
Date of Patent:
November 17, 2020
Assignee:
MEDIMMUNE LIMITED
Inventors:
Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ryan Fleming, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
Abstract: A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound.
Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
Type:
Grant
Filed:
December 15, 2016
Date of Patent:
November 3, 2020
Assignee:
AMGEN INC.
Inventors:
Agnes E. Hamburger, Cen Xu, Hong Sun, Yuan D. Shih, Dohan Weeraratne
Abstract: Humanized or chimeric anti-CD81 (cluster of differentiation 81) monoclonal antibodies are provided. The antibodies bind to human CD81, and find use in various therapeutic methods, including without limitation the reduction or prevention of tumor metastasis. Further provided are heavy chain and light chain variable region sequences as well as associated complementarity-determining region (CDR) sequences.
Type:
Grant
Filed:
June 14, 2017
Date of Patent:
October 27, 2020
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Shoshana Levy, Aurelien Marabelle, Ranjani Rajapaksa, Felipe Vences-Catalan, Chiung-Chi Kuo, Jie Liu, Ronald Levy
Abstract: The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.
Type:
Grant
Filed:
May 13, 2020
Date of Patent:
October 6, 2020
Assignee:
Surface Oncology, Inc.
Inventors:
Scott Chappel, Andrew Lake, Michael Warren, Austin Dulak, Erik Devereaux, Pamela M. Holland, Tauqeer Zaidi, Matthew Rausch, Bianka Prinz, Nels P. Nielson, Sonia Das
Abstract: The present invention relates to a cancer treatment composition for inhibiting angiogenesis, and a preparation method therefor. An angiogenesis inhibitor according to the present invention is a cancer treatment composition comprising a fusion protein comprising a vascular endothelial growth factor-binding domain of vascular endothelial growth factor receptor 1 (VEGFR1) and a b1 domain of neuropilin-1 (NRP1). The novel fusion protein is an angiogenesis inhibitor for blocking the binding of VEGF to a receptor in the cell membrane, and has an effect of inhibiting the proliferation of cancer cells and the growth and metastasis of cancer. In addition, the fusion protein can be used as an anti-cancer agent and exhibits an effective anti-cancer effect at a lower dose than that of a conventional angiogenesis inhibitor.
Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
Type:
Grant
Filed:
September 13, 2019
Date of Patent:
September 22, 2020
Assignee:
Shattuck Labs, Inc.
Inventors:
Taylor Schreiber, George Fromm, Suresh De Silva
Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
Type:
Grant
Filed:
September 13, 2018
Date of Patent:
September 22, 2020
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER
Abstract: The present invention relates to methods for selecting a headache patient responsive to treatment with an anti-CGRP antibody and to methods for reducing headache frequency in the selected patient comprising administering an anti-CGRP antibody.
Type:
Grant
Filed:
March 1, 2018
Date of Patent:
September 8, 2020
Assignee:
Beth Israel Deaconess Medical Center, Inc.
Abstract: The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.
Type:
Grant
Filed:
December 8, 2016
Date of Patent:
September 8, 2020
Assignee:
The Regents of the University of California
Inventors:
Kevin E. Healy, Eda Isil Altiok, David V. Schaffer, Wesley M. Jackson
Abstract: Neuregulin-1 (NRG1) or a fragment thereof or vitamin B12 for use in maintaining or increasing muscle function and/or mass in an ageing subject, and/or substantially preventing or reducing muscle wasting in an ageing subject.
Abstract: The present invention relates to a p75NTR neurotrophin binding protein, p75NTR(NBP), for use in the treatment of pain and/or a symptom of pain.
Abstract: A method for searching for a substance suppressing a target odor through cross-adaptation is provided. A method for selecting a substance inducing cross-adaptation of a target odor includes: searching olfactory receptor polypeptides to identify an olfactory receptor polypeptide responding to a causative substance of the target odor; adding a test substance, which is different from the causative substance of the target odor, to the identified olfactory receptor polypeptide to measure response thereof; and selecting the test substance which activates the response of the olfactory receptor polypeptide as the substance inducing the cross-adaptation of the target odor.
Abstract: The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.
Type:
Grant
Filed:
March 13, 2019
Date of Patent:
August 11, 2020
Assignee:
Surface Oncology, Inc.
Inventors:
Scott Chappel, Andrew Lake, Michael Warren, Austin Dulak, Erik Devereaux, Pamela M. Holland, Tauqeer Zaidi, Matthew Rausch, Bianka Prinz, Nels P. Nielson, Sonia Das
Abstract: Isolated or recombinant anti-LGR4 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
Type:
Grant
Filed:
December 9, 2016
Date of Patent:
August 4, 2020
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
Type:
Grant
Filed:
December 19, 2017
Date of Patent:
August 4, 2020
Assignee:
OncoMed Pharmaceuticals, Inc.
Inventors:
Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
Abstract: The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.
Abstract: The present invention provides a pharmaceutical preparation for treating a cardiovascular disease. Particularly, the present invention provides a formula of a neuregulin pharmaceutical preparation. The formula consist of neuregulin polypeptide, a buffer, a stabilizer, an excipient, a salt, and another component, can ensure the long-term stability of the neuregulin polypeptide, and can be used for treating a heart failure patient or a patient in a risk of the heart failure.